Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial.

导出 OA

翻译打印收藏纠错

第一作者： Shaukat,Ali

第一单位： Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan. ali.shaukat@duhs.edu.pk.

作者： Shaukat,Ali ^[1] ; Elisha,Shalim ^[2] ; Farah,Farhan ^[3] ; Fatima,Anjum ^[2] ; Ayesha,Ali ^[4] ; Syed Muneeb,Uddin ^[2] ; Faisal,Shahab ^[2] ; Mustafa,Haider ^[2] ; Iqra,Ahmed ^[2] ; Mir Rashid,Ali ^[2] ; Sadaf,Khan ^[2] ; Sadia,Rao ^[2] ; Kabeer,Guriro ^[2] ; Saud,Elahi ^[2] ; Muhammad,Ali ^[3] ; Tehreem,Mushtaq ^[2] ; Muneeba Ahsan,Sayeed ^[2] ; Sheikh Muhammad,Muhaymin ^[5] ; Shoba,Luxmi ^[2] ; Saifullah ^[6] ; Saeed,Qureshi ^[3]

作者单位： Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan. ali.shaukat@duhs.edu.pk. ^[1] Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan. ^[2] Department of Biotechnology, University of Karachi, Karachi, Pakistan. ^[3] Dow Research Institute Of Bio-Technology And Bio-Sciences (DRIBBS), Dow University of Health Sciences, Karachi, Pakistan. ^[4] Sindh Infectious Disease Hospital and Research Center, Karachi, Pakistan. ^[5] Dow University Hospital, Dow University of Health Sciences, Karachi, Pakistan. ^[6]

关键词 Anti-COVID-19 IVIG Hyperimmune Intravenous Novel coronavirus Passive immunization Pneumonia Polyclonal antibodies Pooled convalescent plasma Randomized controlled trial SARS CoV-2